|
Mar 3
|
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
|
|
Mar 1
|
Apellis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
|
|
Mar 1
|
Apellis Pharmaceuticals Inc (APLS) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ...
|
|
Mar 1
|
Q4 2024 Apellis Pharmaceuticals Inc Earnings Call
|
|
Feb 28
|
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics
|
|
Feb 28
|
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 28
|
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 25
|
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
|
|
Feb 24
|
Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
|
|
Feb 23
|
Why Apellis Pharmaceuticals, Inc. (APLS) is the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 21
|
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 21
|
High Growth Tech Stocks In The United States To Watch
|
|
Feb 20
|
Is Apellis Pharmaceuticals (APLS) One of the Most Oversold Healthcare Stocks to Buy Now?
|
|
Feb 20
|
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
|
|
Feb 18
|
Apellis Pharmaceuticals (APLS): Among Top Insider Stock Buys And Sells In January
|
|
Jan 3
|
Exploring 3 High Growth Tech Stocks In The United States
|
|
Sep 25
|
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
|
|
Sep 23
|
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
|
|
Sep 6
|
Why Is SpringWorks Therapeutics (SWTX) Up 11.7% Since Last Earnings Report?
|
|
Sep 6
|
Exploring 3 High Growth Tech Stocks in the United States
|